Soliqua® 100/33 Insulin Glargine and Lixisenatide Injection: Prefilled SoloStar® Pen for Diabetes Management

USAMP#73983027SKU: 00024576105Soliqua®
rxLicense

License Required

wishlistAltwishlistAlt
Soliqua 100/33 Insulin Glargine/Lixisenatide Prefilled Pen

Product Spotlight

  • Administered subcutaneously once daily using the Soliqua 100/33 SoloStar® pen for consistent and controlled diabetes management.
  • Each dose combines 15 Units of Lantus® (Insulin Glargine) with 5 mcg of Lixisenatide, a potent GLP-1 receptor agonist, to improve glycemic control in adults with type 2 diabetes.
  • Formulated with a precise ratio of 1 Unit of Lantus® to 0.33 mcg of Lixisenatide, ensuring accurate dosing and effective blood sugar management.